Mismatch repair deficiency occurs very rarely in seminomas.

Seminoma immunohistochemistry microsatellite instability (MSI) mismatch repair (MMR)

Journal

Translational andrology and urology
ISSN: 2223-4691
Titre abrégé: Transl Androl Urol
Pays: China
ID NLM: 101581119

Informations de publication

Date de publication:
Mar 2021
Historique:
entrez: 14 4 2021
pubmed: 15 4 2021
medline: 15 4 2021
Statut: ppublish

Résumé

Dense tumor-associated lymphocyte infiltration is linked to mismatch repair (MMR) deficiency in colorectal and endometrial cancer. MMR deficiency is of high clinical importance as MMR deficient cancers tend to react favorably to treatment with immune checkpoint inhibitors. Strong lymphocytic infiltration is a morphological hallmark of seminomas. We thus asked whether seminomas may exhibit MMR deficiency at relevant frequency. To screen for tumors with MMR deficiency, protein expression of MLH1, PMS2, MSH2, and MSH6 was analyzed by immunohistochemistry (IHC) on a tissue microarray (TMA) containing 574 seminomas. In total, 536 cases were evaluable resulting in 481 seminomas with unequivocally intact MMR protein expression. In 55 cancers, one or several IHC stains were equivocal and lacked detectable MMR protein in both tumor and stromal cells. Large section IHC analysis of all 55 equivocal cases demonstrated substantial staining issues due to improper fixation in 54 cases and identified one tumor with clear-cut MLH1 and PMS2 protein loss. This seminoma showed homogeneous loss of MLH1 and PMS2 in the entire tumor mass whereas minor adjacent foci of associated germ cell neoplasia in situ (GCNIS) were MMR intact. Polymerase chain reaction (PCR) analysis using the 5 microsatellite loci of the "Bethesda Panel" revealed instability in 1 of 4 interpretable loci ("MSI-low") and additional instability of the complex tetra-penta repeat locus MYCL1 in this tumor. In summary, one single seminoma with MMR deficiency, characterized by protein loss of MLH1 and PMS2, was identified among 536 interpretable seminomas (0.19%). MMR deficiency is not a relevant determinant of lymphocyte influx in seminoma.

Sections du résumé

BACKGROUND BACKGROUND
Dense tumor-associated lymphocyte infiltration is linked to mismatch repair (MMR) deficiency in colorectal and endometrial cancer. MMR deficiency is of high clinical importance as MMR deficient cancers tend to react favorably to treatment with immune checkpoint inhibitors. Strong lymphocytic infiltration is a morphological hallmark of seminomas. We thus asked whether seminomas may exhibit MMR deficiency at relevant frequency.
METHODS METHODS
To screen for tumors with MMR deficiency, protein expression of MLH1, PMS2, MSH2, and MSH6 was analyzed by immunohistochemistry (IHC) on a tissue microarray (TMA) containing 574 seminomas.
RESULTS RESULTS
In total, 536 cases were evaluable resulting in 481 seminomas with unequivocally intact MMR protein expression. In 55 cancers, one or several IHC stains were equivocal and lacked detectable MMR protein in both tumor and stromal cells. Large section IHC analysis of all 55 equivocal cases demonstrated substantial staining issues due to improper fixation in 54 cases and identified one tumor with clear-cut MLH1 and PMS2 protein loss. This seminoma showed homogeneous loss of MLH1 and PMS2 in the entire tumor mass whereas minor adjacent foci of associated germ cell neoplasia in situ (GCNIS) were MMR intact. Polymerase chain reaction (PCR) analysis using the 5 microsatellite loci of the "Bethesda Panel" revealed instability in 1 of 4 interpretable loci ("MSI-low") and additional instability of the complex tetra-penta repeat locus MYCL1 in this tumor.
CONCLUSIONS CONCLUSIONS
In summary, one single seminoma with MMR deficiency, characterized by protein loss of MLH1 and PMS2, was identified among 536 interpretable seminomas (0.19%). MMR deficiency is not a relevant determinant of lymphocyte influx in seminoma.

Identifiants

pubmed: 33850739
doi: 10.21037/tau-20-1355
pii: tau-10-03-1048
pmc: PMC8039613
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1048-1055

Informations de copyright

2021 Translational Andrology and Urology. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau-20-1355). All authors have no conflicts of interest to declare.

Références

Virchows Arch. 2020 May;476(5):745-752
pubmed: 31811435
PLoS One. 2015 Mar 27;10(3):e0121980
pubmed: 25816162
JCO Precis Oncol. 2017;2017:
pubmed: 29850653
Eur Urol Focus. 2020 Jan 15;6(1):122-130
pubmed: 30025711
Int J Clin Exp Pathol. 2018 May 01;11(5):2579-2587
pubmed: 31938371
Cancer Control. 2004 Nov-Dec;11(6):374-87
pubmed: 15625525
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
J Clin Oncol. 2019 Feb 1;37(4):286-295
pubmed: 30376427
Cell Oncol (Dordr). 2020 Jun;43(3):421-430
pubmed: 32141029
Am J Clin Pathol. 2020 Feb 8;153(3):387-395
pubmed: 31802108
Cancer Res. 2002 May 15;62(10):2758-60
pubmed: 12019150
Cancers (Basel). 2019 Oct 11;11(10):
pubmed: 31614500
Br J Cancer. 1995 Sep;72(3):642-5
pubmed: 7669575
Histopathology. 2020 Feb;76(3):486-489
pubmed: 31442315
Int J Cancer. 2005 Jan 10;113(2):329-35
pubmed: 15386408
Cancer Prev Res (Phila). 2012 Apr;5(4):574-82
pubmed: 22262812
Appl Immunohistochem Mol Morphol. 2017 Jan;25(1):12-24
pubmed: 26371427
Nature. 2012 Aug 23;488(7412):504-7
pubmed: 22820252
Cancer. 2001 Jun 15;91(12):2417-22
pubmed: 11413533
Cell Rep. 2018 Jun 12;23(11):3392-3406
pubmed: 29898407
Cancer Res. 1998 Nov 15;58(22):5248-57
pubmed: 9823339
Ann Oncol. 2019 Aug 1;30(8):1232-1243
pubmed: 31056702
Med Sci Monit. 2016 Aug 16;22:2886-92
pubmed: 27527654
J Clin Oncol. 2015 Dec 20;33(36):4301-8
pubmed: 26552419
Cell Oncol (Dordr). 2017 Aug;40(4):341-355
pubmed: 28536927
Oncotarget. 2016 Apr 23;7(23):34546-57
pubmed: 27120810
JAMA Oncol. 2019 Apr 1;5(4):551-555
pubmed: 30452494
Biomed Res Int. 2013;2013:396272
pubmed: 23555086
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
Int J Cancer. 2008 Apr 15;122(8):1774-7
pubmed: 18076065
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Br J Cancer. 2005 May 9;92(9):1746-53
pubmed: 15856045
Int J Gynecol Cancer. 2015 Sep;25(7):1165-72
pubmed: 26111272
Andrology. 2016 Sep;4(5):866-72
pubmed: 27153176
Pharmacol Ther. 2018 Sep;189:45-62
pubmed: 29669262
J Clin Oncol. 2009 May 1;27(13):2129-36
pubmed: 19289622
Indian J Pathol Microbiol. 2018 Oct-Dec;61(4):520-525
pubmed: 30303141
Gynecol Oncol. 2020 Mar;156(3):669-675
pubmed: 31924330
Urol Oncol. 2020 May;38(5):488-495
pubmed: 32067846
Anticancer Res. 2005 Nov-Dec;25(6B):4319-24
pubmed: 16309235
Cancer Biol Ther. 2004 Nov;3(11):1152-8; discussion 1159-61
pubmed: 15492498
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Pathology. 2019 Jan;51(1):110-113
pubmed: 30497803
Nature. 2015 May 7;521(7550):81-4
pubmed: 25707793

Auteurs

David Dum (D)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Stefan Steurer (S)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Ronald Simon (R)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Pia Victoria Zimmermann (PV)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Eike Burandt (E)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Till Sebastian Clauditz (TS)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Margit Fisch (M)

Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Michael Rink (M)

Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Roland Dahlem (R)

Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Wolfgang Höppner (W)

Department of Urology, Itzehoe Medical Center, Itzehoe, Germany.

Henrik Zecha (H)

Department of Urology, Albertinen Clinic, Hamburg, Germany.

Ousman Doh (O)

Department of Urology, Regio Medical Center Elmshorn, Elmshorn, Germany.

Cord Matthies (C)

Department of Urology, Bundeswehr Hospital Hamburg, Hamburg, Germany.

Waldemar Wilczak (W)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Guido Sauter (G)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Christoph Fraune (C)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Classifications MeSH